Biotech Values

[mcbio]

I did a quick listen of the call but since I don't follow the company closely wonder what others think about it. The one thing that would concern me on the call they talked about possibly merging with another oncology company out there. Its one thing to focus on one area when you already have expertise but to buy/merge is a bit of a risk in my book.

I haven't listened to the call yet but am long PGNX so will chime in here. This announcement makes sense to me. Relistor is now entirely in Salix's hands so there's nothing more for PGNX to do with that asset. The HIV-entry inhibitor was the most advanced asset behind Relistor, in Phase 2, but we've discussed before on here how that asset seems to be a dud. The next most advanced asset is the PSMA ADC in Phase 1 for prostate cancer and this at least seems to be an interesting target, even if they don't have any clear PoC at this point. I also posted awhile back about PI3K inhibitors and thought it interesting that PGNX has a dual PI3K/MNK inhibitor (#msg-57049109 ). So, the fact that PGNX announced they will focus on oncology going forward comes as no big surprise to me.

All told, I'm mainly holding PGNX for Relistor, but I will be more than happy if there is a positive development in their oncology programs going forward.